In this article, we will discuss Romidepsin (Dosage Overview). So, let’s get started.
Romidepsin is indicated for treatment of cutaneous T-cell lymphoma (CTCL)
in patients who have received at least one prior systemic therapy.
The recommended dose of romidepsin is 14 mg/m² administered intravenously over a 4-hour period on days 1, 8 and 15 of a 28-day cycle. Cycles should be repeated every 28 days provided that the patient continues to
benefit from and tolerates the therapy.